In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy.

Autor: Dandoy CE; Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, Ohio. Electronic address: Christopher.Dandoy@CCHMC.org., Adams J; Stephenson Cancer Center, OU Health Science Center The University of Oklahoma, Oklahoma City, Oklahoma., Artz A; Division of Leukemia, Department of Hematology and HCT, City of Hope, Duarte, California., Bredeson C; Ottawa Hospital Research Institute, Division of Hematology, University of Ottawa, Ottawa, Canada., Dahi PB; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, New York., Dodd T; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee., Jaglowski S; Department of Pediatrics and Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Lehmann L; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts., LeMaistre CF; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee., Mian A; Department of Pediatric Hematology and Oncology, Department of Pediatrics at Dell Medical School, The University of Texas at Austin, Austin, Texas., Neal A; Department of Bone Marrow Transplant and Cellular Therapy, The Ohio State University Wexner Medical Center, Columbus, Ohio., Page K; Department of Pediatrics and Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Rizzo JD; Department of Pediatrics and Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Rotz S; Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, Ohio., Sorror M; Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington., Steinberg A; Adult Stem Cell Transplantation, Westchester Medical Center, New York Medical College, Valhalla, New York., Viswabandya A; Department of Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Howard DS; Department of Internal Medicine, Section of Hematology and Oncology, Stem Cell Transplant and Cellular Therapy Program, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, North Carolina.
Jazyk: angličtina
Zdroj: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Oct; Vol. 30 (10), pp. 942-954. Date of Electronic Publication: 2024 Jul 25.
DOI: 10.1016/j.jtct.2024.07.011
Abstrakt: Immune effector cell (IEC) therapy represents a transformative advancement in oncology, leveraging the immune system to combat various malignancies. This article outlines a comprehensive framework for establishing and maintaining quality standards in IEC therapy amidst rapid scientific and clinical advancements. We emphasize the integration of structured process measures, robust quality assurance, and meticulous outcome evaluation to ensure treatment efficacy and safety. Key components include multidisciplinary expertise, stringent accreditation protocols, and advanced data management systems, which facilitate standardized reporting and continual innovation. The collaborative effort among stakeholders-ranging from patients and healthcare providers to regulatory bodies-is crucial in delivering high-quality IEC therapies. This framework aims to enhance patient outcomes and cement the role of IEC therapy as a cornerstone of modern oncology, promoting continuous improvement and adherence to high standards across the therapeutic spectrum.
(Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: